Stock Financial Ratios, Dividends, Split History

QHC / Quorum Health Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price4.44
Volume247,300.00
Market Cap ($M)128.05
Enterprise Value ($M)1,338.73
Book Value ($M)2.24
Book Value / Share0.07
Price / Book57.09
NCAV ($M)-1,143.36
NCAV / Share-38.04
Price / NCAV-0.11
Share Statistics
Common Shares Outstanding 30,201,415
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Common Stock Shares Outstanding 30,294,895
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.09
Return on Assets (ROA)-0.06
Return on Equity (ROE)-0.56
Balance Sheet (mrq) ($M)
Assets1,751.26
Liabilities1,732.87
Quick Ratio1.51
Current Ratio1.64
Income Statement (mra) ($M)
Health Care Organization Patient Service Revenue Provisionfor Bad Debts255,485,000.00
Discounts Included In Health Care Organization Patient Service Revenue428,779,000.00
Contractual Allowances Included In Health Care Organization Patient Service Revenue9,173,711,000.00
Health Care Organization Revenue2,327,655,000.00
Health Care Organization Patient Service Revenue11,930,145,000.00
Health Care Organization Revenue Net Of Patient Service Revenue Provisions2,072,170,000.00
Operating Income-12.14
Net Income-112.36
Earnings Per Share Basic And Diluted-4.06
Cash Flow Statement (mra) ($M)
Cash From Operations66.97
Cash from Investing-38.27
Cash from Financing-38.27
Identifiers and Descriptors
CUSIP74909E106
Central Index Key (CIK)1650445
Related CUSIPS
74909E114

Split History

Stock splits are used by Quorum Health Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

What Falling Estimates & Price Mean for Quorum Health (QHC)

2018-06-04 zacks
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. One such stock that you may want to consider dropping is Quorum Health Corporation (QHC - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. (8-0)

Quorum Health Corporation 2018 Q1 - Results - Earnings Call Slides

2018-05-10 seekingalpha
The following slide deck was published by Quorum Health Corporation in conjunction with their 2018 Q1 earnings call. (4-1)

Quorum Health's (QHC) CEO Tom Miller on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good morning. My name is Heidi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Quorum Health Corporation First Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. (16-0)

BRIEF-Quorum Health Says As Of March 31, Co Incurred About $13.7 Mln Of Costs Related To Closure Of Affinity

2018-05-10 reuters
* QUORUM HEALTH SAYS AS OF MARCH 31, CO INCURRED ABOUT $13.7 MILLION OF COSTS RELATED TO CLOSURE OF AFFINITY - SEC FILING (4-0)

CUSIP: 74909E106